No Data
Nanxin Pharmaceutical: 2024 Annual Results Express Announcement
2024 Annual Results Express Announcement
Nanxin Pharmaceutical: 2024 Annual Results Forecast Announcement
2024 Annual Results Forecast Announcement
Hunan Nucien Pharmaceutical Gets China Marketing Nod for Anti-Allergy Drug
Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH): Hydrochloride Fexofenadine oral suspension has obtained the Pharmaceutical registration certificate.
Gelonghui, on January 3rd, reported that Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) announced that its subsidiary, Guangzhou Nucien Pharmaceutical Co., Ltd., received the drug registration certificate for oral suspension of fexofenadine hydrochloride issued by the National Medical Products Administration. The indications for oral suspension of fexofenadine hydrochloride include: (1) relief of symptoms associated with seasonal allergic rhinitis in children aged 2 years and older and adults. (2) relief of skin symptoms of chronic idiopathic urticaria in children aged 6 months and older and adults, which can reduce itching and decrease the number of hives. Fexofenadine hydrochloride is a selective H1 receptor antagonist, which is the active form of terfenadine.
Hunan Nucien Pharmaceutical Co., Ltd. (SHSE:688189) May Have Run Too Fast Too Soon With Recent 29% Price Plummet